Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes patients have been found to cause severe and debilitating joint pain, according to the U.S. Food and Drug Administration (FDA).
DPP-4 inhibitors like Januvia (sitagliptin), Onglyza (saxagliptin), Tradjenta (linagliptin), and Nesina (alogliptin) are used, along with diet and exercise, to lower blood sugar in adults who suffer from type 2 diabetes.
Incretin, a natural hormone, tells the body to release insulin after eating, which lowers blood sugar.
When the body makes incretin, an enzyme known as DPP-4 removes it from the body in people without diabetes.
But some people with type 2 diabetes do not make enough incretin, so DPP-4 inhibitors are prescribed to help keep blood sugar in a target range that will help avoid low blood sugar and weight gain.
The FDA identified 33 cases of severe joint pain in patients taking DPP-4 inhibitors from October 2006 (when the first of the drugs was approved) through December 31, 2013.
According to the FDA, the most frequent problems (28) occurred with Januvia use.
Five were linked with Onglyza, two with Tradjenta, and one with Nesina.
Other side effects linked to DPP-4 inhibitors include:
According to the FDA, patients started having symptoms from the first day up to years after they started taking a DPP-4 inhibitor, but after the patients discontinued use of the medication, their symptoms stopped, usually in one month or less.
Some patients developed severe joint pain again when they restarted the same or another DPP-4 inhibitor.
The FDA does not recommend that patients should stop taking their medications.
They should instead contact their physician if they experience severe and persistent joint pain.
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
Camp Lejeune’s water contamination issue spanned several decades starting in the 1950s. Exposure to these chemicals has been linked to various serious health issues, including cancer, organ diseases, and death.
Research is increasingly suggesting a link between the use of Tylenol during pregnancy and the development of neurodevelopmental disorders, such as autism and ADHD, in infants.
Legal action is being taken against manufacturers of Aqueous Film-Forming Foam (AFFF), a chemical used in fighting fires. The plaintiffs allege that exposure to the foam caused health issues such as cancer, organ damage, and birth and fertility issues.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
Weis Market Inc., a Mid-Atlantic food retailer based in Sunbury, Pennsylvania, has recalled its 48-ounce containers of Weis Quality Brownie Moose Tracks Ice Cream because the product may contain traces of egg, an allergen not declared on the ingredient statement label, according to the FDA.
Marlex Pharmaceuticals, Inc., of New Castle, Delaware, has announced a voluntary, consumer-level recall of one lot of Digoxin Tablets USP, 0125mg, as well as one lot of Digoxin Tablets USP, 0.25mg, because the labels of both products have been mixed up, according to the FDA.